Favipiravir ilacı uygulanan ratlardaki böbrek ve kalp metabolit profillerinin yüksek rezolüsyonlu NMR spektroskopisi kullanılarak incelenmesi ve analizi
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Aralık 2019'da Çin'in Wuhan kentinde ciddi solunum yolu hastalıklarına neden olan virüse Dünya Sağlık Örgütü tarafından SARS-CoV-2 ve virüsün yol açtığı hastalığa COVID-19 adı verildi. Türkiye Cumhuriyeti Sağlık Bakanlığı tarafından ilk vaka 11 Mart 2020 tarihinde açıklandı. Antiviral ilaçların belirtilerin başlamasından kısa bir süre sonra kullanılmasının, klinik hastalığın seyrini kısalttığı ve viral bulaşmayı azalttığı belirtilmiştir. Bu antiviral ajanlardan birisi de Türkiye'de COVID-19 tedavisinde yaygın olarak kullanılan Favipiravir'dir. Seçici bir RNA polimeraz inhibitör ajanı olan Favipiravir, influenza virüsünün yanı sıra RNA virüslerine karşı da güçlü antiviral aktivite göstermektedir. Ülkemizde COVID-19 tedavisinde kullanılan ilaçlar listesinden Kasım 2021'de çıkarılan Favipiravirin metabolik düzeyde etkileri merak edilmektedir. Özellikle Favipiravir kullanımının artmasıyla bağlantılı olarak kalp krizi ve böbrek fonksiyon bozukluğu şikâyetlerinde artış gözlemlenmiştir. Bu durum, bizleri yüksek dozlarla kullanılmaya başlanan Favipiravir ilacının bu organlar üzerindeki metabolik etkilerini incelemeye yönlendirmiştir. Bu tez çalışması ile Favipiravir kullanımının böbrek ve kalp metabolit profili üzerinde bir etki yaratıp yaratmadığının belirlenmesi amaçlanmıştır. Bu amaç doğrultusunda, kontrol grubu (n=20), düşük doz Favipiravir (n=20) ve yüksek doz Favipiravir (n=20) uygulanan ratlardan alınan böbrek ve kalp örneklerinin 1H-NMR analizi yapılmıştır. Elde edilen metabolomik verisi çok değişkenli istatistiksel analiz ile incelenmiş ve Favipiravir ilacının metabolitler üzerindeki etkisi tespit edilmiştir. Anahtar Kelimeler: Favipiravir, Covid-19, Nükleer Manyetik Rezonans, Metabolomik, Çok Değişkenli İstatistiksel Analiz
The virus that caused serious respiratory diseases in Wuhan, China in December 2019 was named as SARS-CoV-2 by the World Health Organization, and the disease caused by the virus was named as COVID-19. The first case was announced by the Ministry of Health of the Republic of Turkey on March 11, 2020. It has been stated that the use of antiviral drugs shortly after the onset of symptoms shortens the course of clinical disease and reduces viral shedding. One of these antiviral agents is Favipiravir, which was widely used in the treatment of COVID-19 in Turkey. Favipiravir, a selective RNA polymerase inhibitory agent, shows potent antiviral activity against RNA viruses as well as influenza virus. The metabolic effects of Favipiravir, which was removed from the list of drugs used in the treatment of COVID-19 in our country in November 2021, are questioned. Particularly, an increase in complaints of heart attacks and kidney dysfunction has been observed in correlation with the increased use of Favipiravir. This situation has prompted us to investigate the metabolic effects of high doses of Favipiravir on these organs. The aim of this thesis study is to determine whether the use of Favipiravir affects the metabolic profile of the kidney and heart for this purpose, 1H-NMR analysis was performed on kidney and heart samples obtained from rats treated with a control group (n=20), low-dose Favipiravir (n=20), and high-dose Favipiravir (n=20). The obtained metabolomic data were analyzed using multivariate statistical analysis to identify the effect of Favipiravir on metabolites. Keeywords: Favipiravir, Covid-19, Nuclear Magnetic Resonance, Metabolomics, Multivariate Statistical Analysis
The virus that caused serious respiratory diseases in Wuhan, China in December 2019 was named as SARS-CoV-2 by the World Health Organization, and the disease caused by the virus was named as COVID-19. The first case was announced by the Ministry of Health of the Republic of Turkey on March 11, 2020. It has been stated that the use of antiviral drugs shortly after the onset of symptoms shortens the course of clinical disease and reduces viral shedding. One of these antiviral agents is Favipiravir, which was widely used in the treatment of COVID-19 in Turkey. Favipiravir, a selective RNA polymerase inhibitory agent, shows potent antiviral activity against RNA viruses as well as influenza virus. The metabolic effects of Favipiravir, which was removed from the list of drugs used in the treatment of COVID-19 in our country in November 2021, are questioned. Particularly, an increase in complaints of heart attacks and kidney dysfunction has been observed in correlation with the increased use of Favipiravir. This situation has prompted us to investigate the metabolic effects of high doses of Favipiravir on these organs. The aim of this thesis study is to determine whether the use of Favipiravir affects the metabolic profile of the kidney and heart for this purpose, 1H-NMR analysis was performed on kidney and heart samples obtained from rats treated with a control group (n=20), low-dose Favipiravir (n=20), and high-dose Favipiravir (n=20). The obtained metabolomic data were analyzed using multivariate statistical analysis to identify the effect of Favipiravir on metabolites. Keeywords: Favipiravir, Covid-19, Nuclear Magnetic Resonance, Metabolomics, Multivariate Statistical Analysis
Açıklama
07.12.2024 tarihine kadar kullanımı yazar tarafından kısıtlanmıştır.
Anahtar Kelimeler
Biyoistatistik, Biostatistics, Biyokimya
